Imatinib Mesylate 220127-57-1

In-house Standard

Product categories

New Products

Product Details

Product Information

Product name	Imatinib Mesylate
Molecular Formula	C30H35N7O4S
Molecular Weight	589.71
CAS No.	220127-57-1
Quality Standard	In-house standard
Appearance	White or slightly yellow crystalline powder

COA of Imatinib Mesylate

TEST ITEMS	SPECIFICATION	RESULTS
Appearance	White or slightly yellow crystalline powder, homogeneous and with fine grain size. No foreign particles are observed.	Slightly yellow crystalline Powder
Solubility	Soluble in water and in acids solutions, slightly soluble in methanol insoluble in acetone, acetonitrile and dilute hydroxyl alkaline solution	Confirm
Identification	Complies	Confirm
Water	≤1.0%	0.8%
Heavy metals	≤20ppm	10ppm
Melting range	212 – 220℃	214-216℃
Residue on ignition	≤0.1%	0.08%
Particle size	90% < 100 μm 50% < 50 μm	Confirm
Bulk density	NLT 0.4g/ml	0.6g/ml
Chromatographic purity	Individual impurities: ≤0.2% Total impurities: ≤0.5%	0.16% 0.32%
Assay	98.5%-102.0% of Imatinib mesylate, calculated on anhydrous basis.	99.70%
Residual solvents	Ethyl acetate: ≤5000ppm	Confirm
	Acetone: ≤5000ppm	Confirm
	N,N-Dimethylformamide: ≤880ppm	Confirm
	Methanol: ≤3000ppm	Confirm
	Dichloromethane: ≤300ppm	Confirm

We provide you with high-quality imatinib mesylate powder and imatinib mesylate price is very reasonable and competitive.

Usage

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl,
the causal agent in chronic myelogenous leukemia.

As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of
dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

1. A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)

2. Echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis

3. Anticancer

*Products under the patent are only for R&D use